The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study

BACKGROUND: Paclitaxel plus S-1(PTXS) has shown definite efficacy for advanced gastric cancer. However, the efficacy and safety of this regimen in neoadjuvant setting for locally advanced gastric cancer (LAGC) are unclear. This study aimed to compare the efficacy of neoadjuvant chemotherapy (NAC) PT...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chenghai, Wu, Binghong, Yang, Hong, Yao, Zhendan, Zhang, Nan, Tan, Fei, Liu, Maoxing, Xu, Kai, Chen, Lei, Xing, Jiadi, Cui, Ming, Su, Xiangqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703660/
https://www.ncbi.nlm.nih.gov/pubmed/36443694
http://dx.doi.org/10.1186/s12885-022-10230-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703660/
https://www.ncbi.nlm.nih.gov/pubmed/36443694
http://dx.doi.org/10.1186/s12885-022-10230-1

Ejemplares similares